Kadono, Yoshifumi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Taiki Kamijima, Chikashi Seto, Akinobu Takano, Satoshi Yotsuyanagi, Ryunosuke Nakagawa, Tohru Miyagi, Shuhei Aoyama, Hideki Asahi, Rie Fukuda, and Atsushi Mizokami. “Favorable Response of Pembrolizumab As Second-Line Therapy for Advanced Urothelial Carcinoma With Only Small Lesions to Not Be Considered Measurable by RECIST”. Urology Journal 19, no. 03 (December 20, 2021): 202-208. Accessed June 26, 2022. https://journals.sbmu.ac.ir/urolj/index.php/uj/article/view/6652.